类风湿关节炎(RA)是一种常见的以细胞与体液免疫功能异常、滑膜炎症持续反复发作、关节内软骨和骨质破坏为主要特征的自身免疫性疾病. 患者可出现严重的关节畸形及功能丧失,有较高的致残率及病死率,不仅严重影响患者的生活质量,还给社会带来了巨大的经济负担. 近年来,随着对RA发病机制研究的不断深入,一些靶向治疗药物相继应用于临床. 这些药物具有良好的靶向性及特异性,为难治性RA患者的治疗带来了新的希望.“,”Rheumatoid arthritis ( RA ) is a common cellular and humoral immune dysfunction autoim-mune disease,with recurrent synovitis sustained,intra-articular cartilage and bone destruction as the main features.The patients probably will have severe joint deformity and loss of function,and high morbidity and mortality.It impacts the life quality of patients,and also brings heavy economic burden to the society.In recent years,with the deepening of its pathogenesis studies,a number of targeted therapies have been used clinically.These drugs have high affinity and specificity which have revolutionized treatment of RA.